Business Context and Reporting Period
Company: Can-Fite Biopharma Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: February 5, 2026
Context: The filing incorporates by reference a press release regarding a clinical milestone for the company's drug candidate, Namodenoson.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a clinical development update and does not contain financial statements or quantitative financial data.
Material Changes
Clinical Milestone: A patient with decompensated liver cirrhosis successfully underwent a liver transplantation following treatment with Namodenoson. This event represents a significant clinical development for the company's pipeline.
Guidance, Outlook, and Risks
Management Commentary: The filing highlights the successful transplantation as a key event, incorporated from the attached press release (Exhibit 99.1).
Outlook: No specific financial guidance or future projections are provided in this text.
Risks: No specific risks or contingencies are detailed in the body of this filing, though clinical trials inherently carry development risks.
Investor Verification Checklist
- Review the full text of the press release (Exhibit 99.1) for detailed clinical data regarding the Namodenoson treatment and transplantation outcome.
- Verify the patient's long-term post-transplant status and any follow-up data not included in this summary.
- Check subsequent filings for any impact of this clinical milestone on the company's cash burn rate or funding requirements.
- Confirm the regulatory status of Namodenoson in relation to this specific indication.